Trends in Anti-Vascular Endothelial Growth Factor Injections Among Medicare Part B Beneficiaries in 2013-2021 and the Step Therapy Era.

ABSTRACT: Purpose: To analyze anti-vascular endothelial growth factor (anti-VEGF) injection trends for Medicare Part B beneficiaries during the period 2013-2021, as well as before and after step therapy implementation. Methods: This study examined ophthalmologists administering intravitreal anti-VEGF injections to Medicare Part B beneficiaries from January 1, 2013 through December 31, 2021. Data were gathered from the Medicare Physician & Other Practitioners - by Provider and Service database and identified using Current Procedural Terminology codes specific to bevacizumab, ranibizumab, and aflibercept. Statistical analyses were conducted using R. Results: Among 26 602 816 total injections performed from 2013 to 2021, relative usage of aflibercept increased by 158.3%, while rela

SUBMITTER: Bryan JM 

PROVIDER: S-EPMC12592112 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature